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Abstract
The aggregation of amyloid-β (Aβ) is postulated to be the crucial event in Alzheimer’s dis-
ease (AD). In particular, small neurotoxic Aβ oligomers are considered to be responsible for
the development and progression of AD. Therefore, elimination of thesis oligomers repre-
sents a potential causal therapy of AD. Starting from the well-characterized D-enantiomeric
peptide D3, we identified D3 derivatives that bind monomeric Aβ. The underlying hypothesis
is that ligands bind monomeric Aβ and stabilize these species within the various equilibria
with Aβ assemblies, leading ultimately to the elimination of Aβ oligomers. One of the hereby
identified D-peptides, DB3, and a head-to-tail tandem of DB3, DB3DB3, were studied in
detail. Both peptides were found to: (i) inhibit the formation of Thioflavin T-positive fibrils; (ii)
bind to Aβmonomers with micromolar affinities; (iii) eliminate Aβ oligomers; (iv) reduce Aβ-
induced cytotoxicity; and (v) disassemble preformed Aβ aggregates. The beneficial effects
of DB3 were improved by DB3DB3, which showed highly enhanced efficacy. Our approach
yielded Aβmonomer-stabilizing ligands that can be investigated as a suitable therapeutic
strategy against AD.
Introduction
There are 4.2 million new cases of dementia worldwide each year with Alzheimer’s disease
(AD) being the most common cause. Currently, there is no causal treatment for AD available
[1, 2].
Intracellular neurofibrillary tangles (NFTs), consisting of hyperphosphorylated tau and
extracellular plaques, consisting predominantly of amyloid-β (Aβ), are the major pathological
hallmarks of AD. The cleavage of the amyloid precursor protein (APP) by the β- and γ- secre-
tases releases Aβ. Various species of Aβ are formed because the N- and C-terminal cleavage
events are non-homogeneous. The most abundant species of Aβ is Aβ(1–40), consisting of 40
amino acids. The second most dominant species is Aβ(1–42) [3, 4].
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According to the amyloid cascade hypothesis the aggregation of Aβ is responsible for the
development and the progression of AD. Various Aβ aggregate species have been described,
including Aβ oligomers and Aβ protofibrils [5]. In particular, soluble, toxic Aβ oligomers are
thought to be responsible for damage of synaptic plasticity, formation of free radicals, disequi-
librium of intracellular calcium distribution, chronic inflammation and increased phosphoryla-
tion of tau [6, 7]. Thus, inhibition of Aβ oligomerization and the elimination of Aβ oligomers
are promising treatment strategies for the development of a causal therapy of AD.
We have previously selected the 12mer all-D-enantiomeric peptide D3 via mirror image
phage display [8, 9]. In vitro, D3 binds to amyloid plaques, reduces Aβ aggregation to regular
fibrils, eliminates Aβ oligomers and converts preformed fibrils into non-amyloidogenic, non-
fibrillar, non-toxic aggregates [10–14]. In vivo, the plaque load and cerebral inflammation of
transgenic mice is reduced after injection of D3 into the brain and cognitive impairment of
transgenic mice is improved after oral application [10, 15, 16]. The original phage library, from
which D3 was selected, coded for about 109 different peptides. A fully randomized 12mer
library would contain 2012 different peptides. That equals 4 x 1015 theoretically possible 12mer
sequences and is absolutely impossible to achieve due to limitations in the transformation effi-
ciency during generation of the original phage library. Thus, it can be expected that variation
of the D3 sequence will lead to even more potent D3 derivatives.
In the present study, we screened for D3 derivatives with optimized efficiency. To facilitate the
screening for various derivatives, peptide microarrays were used because they allowminiaturiza-
tion, parallelization and automation, and enable high-throughput screenings [17, 18]. In addition,
non-natural amino acids and linker groups, like biotin or fluorescein, can be introduced easily.
We screened more than 600 different D3 derivatives for their ability to bind monomeric Aβ and
characterized the five most promising candidates by examining their ability to prevent Aβ fibril for-
mation. For further optimization, the most promising D3 derivative DB3 was modified by design-
ing a head-to-tail tandem peptide, called DB3DB3. Both peptides were characterized in more detail
regarding their affinity to Aβmonomers and their efficiency to eliminate Aβ oligomers.
Material and Methods
Peptides
Aβ(1–42), N-terminally biotinylated Aβ(1–42) and FITC-Aβ(1–42) were purchased from
Bachem (Heidelberg, Germany). D3 (RPRTRLHTHRNR), DB1 (RPITRLHTDRNR), DB2 (RP
ITTLQTHQNR), DB3 (RPITRLRTHQNR), DB4 (RPRTRLRTHQNR) and DB5 (RPITRLQT
HEQR) were purchased from JPT (Berlin, Germany). DB3DB3 (RPITRLRTHQNRRPITRLRT
HQNR) was purchased from peptides&elephants (Potsdam, Germany). All D-peptides con-
sisted of D-enantiomeric amino acids, were C-terminally amidated and> 95% pure.
HFIP pretreatment of Aβ(1–42)
For obtaining monomeric Aβ(1–42), N-terminally biotinylated Aβ(1–42) and FITC-Aβ(1–42)
were dissolved in 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) overnight to a final concentration
of 1 mg/ml and aliquoted. HFIP was evaporated by vacuum concentration (Concentrator 5301,
Eppendorf, Germany) for 20 min and the aliquots were stored at -20°C until further usage.
Peptide Microarrays
Pepspot membranes. In a first generation peptide array, every position of the 12 amino
acid residue D-peptide D3 was replaced against all 20 naturally occurring amino acids in their
D-enantiomeric conformation. The nitrocellulose membrane spotted with these 240 different
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peptides (JPT, Berlin, Germany) was blocked using TBS pH 7.4 with 10% v/v blocking solution
(Roche, Basel, Switzerland) for 2.5 h at room temperature. After 5 min washing with TBS and
0.1% v/v Tween 20 (TBS-T), the membrane was incubated with 5 μMAβ(1–42) in 10 mM
sodium phosphate buffer pH 7.4 for 1 h. The potential of all 240 derivatives to bind monomeric
Aβ was measured by applying 6E10 (BioLegend, San Diego, USA, diluted 1:10.000 in TBS pH
7.4) and a horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Fisher Scien-
tific, Schwerte, Germany, diluted 1:10.000 in TBS pH 7.4). The membrane was washed with
TBS-T pH 7.4 for 2 h. HRP activity was measured after incubation with HRP substrate (Pierce,
Waltham, USA) by using a ChemiDoc 200 detection system (Bio-Rad Laboratories, Munich,
Germany) and the ImageLab software (Bio-Rad Laboratories, Hercules, Munich, Germany).
Pepscan. For the second generation a peptide microarray was produced by Pepscan (Lely-
stad, Netherlands).
For the Pepscan chip, the peptides were covalently coupled on glass slides in triplicate
(spots with diameter of 100 μm). Slides were incubated with 5 μM FITC-Aβ(1–42) in 10 mM
sodium phosphate buffer pH 7.4 for 1 h at room temperature with gentle agitation. After incu-
bation, the slides were washed three times with TBS-T for 10 min, three times with water for 10
min and subsequently dried using a stream of nitrogen gas.
Fluorescence intensity of FITC-Aβ(1–42) bound to the peptide spots was measured by a
FLA800 fluorescence image system (Fujifilm Medical Systems USA Inc, Stamford, USA) with a
slide carrier employing a 473 nm laser for excitation. Digital images were recorded at 5 μm res-
olution. Fluorescence was analyzed by the software AIDA Array Metrix (Raytest, Staubenhardt,
Germany). Signals were integrated for each spot (diameter 80 μm). The background signal was
detected from local dot rings with diameter widths of 150 μm and background ring widths of
30 μm, and subtracted from the peptide spot signal.
Thioflavin T (ThT) Assay
20 μMAβ(1–42) was mixed with 20 μMThioflavin T (ThT) and 31 μg/ml DB3 or DB3DB3 in
10 mM sodium phosphate buffer, pH 7.4. The assay was performed using a non-binding 96 well
plate (Greiner Bio-One, Frickenhausen, Germany). ThT fluorescence was measured every 15 min
at λex = 440 nm and λem = 490 nm in a temperature-controlled plate reader (Polarstar Optima,
BMG, Offenburg, Germany) at 37°C with 1 min agitation before every measurement. Each value
was background corrected using the ThT fluorescence of a peptide solution without Aβ(1–42).
Biolayer interferometry (BLI)
BLI experiments were performed using an Octet RED96 instrument (fortéBIO, PALL Life Sci-
ence, Menlo Park, USA). N-terminally biotinylated Aβ(1–42) was dissolved in HFIP, lyophi-
lized and dissolved in 2 mM aqueous sodium hydroxide (1 mg/ml) in order to destroy any pre-
existing aggregates. The Aβ(1–42) solution was neutralized by dilution in running buffer (20
mM sodium phosphate buffer, pH 7.4) to a final concentration of 20 μg/ml and directly immo-
bilized on Super Streptavidin biosensors (SSA) (fortéBIO, PALL Life Science, Menlo Park,
USA) to a final depth of 3 nm. Ligand biosensors and reference biosensors were quenched with
20 μg/ml biotin for 7 min.
For KD determinations, the binding of a dilution series of DB3 (200, 100, 50, 25, 12.5, 6.25,
3.125 μM) or DBDB3 (20, 10, 5, 2.5, 1.25, 0.625, 0.3125 μM) was detected in parallel to the
ligand biosensors and reference biosensors. A separate buffer cycle was used for double
referencing. For evaluation, steady state response levels were plotted against the applied peptide
concentrations and fitted according to Langmuir´s 1:1 binding model (Hill function with n = 1,
OriginPro 8.5G, OriginLab, Northampton, USA).
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QIAD assay
The quantitative determination of interference with Aβ(1–42) aggregate size distribution
(QIAD) was performed as described before [14]. In brief, 80 μMAβ(1–42) was incubated in 10
mM sodium phosphate buffer, pH 7.4 for 4.5 h at 22°C with 600 rpm agitation. Aβ(1–42)
aggregation was continued for an additional 40 min with or without DB peptide. The obtained
partial size distribution was analyzed by applying density gradient centrifugation. 100 μl of the
incubated sample was placed on top of a gradient with 5 to 50% iodixanol (Optiprep, Axis-
shield, Oslo, Norway) and separated at 259.000 x g for 3 h at 4°C using an ultracentrifuge
(Optima MAX-XP, Beckman Coulter, Brea, USA). Fourteen fractions of 140 μl were taken
from top to bottom. The pellet was dissolved by adding 60 μl of 6 M guanidine hydrochloride
to the centrifugation tube. After boiling for 5 min, the dissolved pellet sample was collected.
The samples were stored at -80°C until further use.
For quantification of the Aβ(1–42) amount in each fraction, reversed-phase high perfor-
mance liquid chromatography (RP-HPLC) was performed using a Zorbax SB-300 C8 column
(Agilent, Böblingen, Germany) connected to an Agilent 1260 Infinity system using 30% (v/v)
acetonitrile with 0.1% (v/v) trifluoroacetic acid (TFA) as the mobile phase with a flow of 1 ml/
min and a column temperature of 80°C. The applied sample volume was 20 μl. The UV absorp-
tion at 214 nm was measured. For quantification of the Aβ(1–42) amount, the area under the
peak representing Aβ(1–42) was calculated and the molar concentration was determined using
a calibration curve.
For additional control and visualization of the Aβ content in each fraction, a 16% tricine-
SDS-PAGE was performed and Aβ(1–42) was visualized by silver staining according to Schag-
ger [19].
MTT cell viability assay
Rat pheochromocytoma PC12 cells (Leibniz Institute DSMZ, Braunschweig, Germany) were
cultivated in DMEMmedium supplemented with 10% fetal bovine serum and 5% horse serum.
10,000 cells per well were seeded on collagen-coated 96 well plates (Gibco, Life technology,
Carlsberg, USA) and incubated in a 95% humidified atmosphere with 5% CO2 at 37°C for 24 h.
To yield oligomeric Aβ, monomerized Aβ(1–42) was preincubated for 4.5 h in sodium phos-
phate buffer at 21°C and 600 rpm agitation. DB peptide was then added at different concentra-
tions and incubated for further 40 min at 21°C and 600 rpm agitation before addition to the
PC12 cells. Final concentrations were 1 μMAβ(1–42) and 0, 2, 1, or 5 μMDB3 or half of the
molar peptide concentrations of DB3DB3. The PC12 cells were further incubated for 24 h in
95% humidified atmosphere with 5% CO2 at 37°C after adding the Aβ-peptide mixture. Cell
viability was then measured using the Cell proliferation Kit I (MTT) (Roche, Basel, Switzer-
land) according to the manufacturer’s instruction. The absorbance of the formazan product
was determined by measuring at 570 nm after subtracting the absorption at 660 nm. For
absorption measurements, a Polarstar Optima plate reader (BMG, Offenburg, Germany) was
used. All results were normalized to cells that were treated with buffer only.
Aβ Aggregation inhibition ELISA
Freshly dissolved monomeric Aβ(1–42) (400 nM in 500 mM Tris-buffer pH 7.4) was incubated
with and without DB peptides in different concentrations (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50 and
100 μM for DB3 or half of the molar concentrations in case of DB3DB3) in a humidity cham-
ber for 23 h at 37°C. The aggregation was analyzed by an enzyme-linked immunosorbent assay
(ELISA). NP27 antibody in bicarbonate/carbonate buffer was used to coat the ELISA plate
overnight. Then the plate was washed in PBS-Tween buffer (1x PBS + 0.05% Tween) and
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blocked for 2 h at room temperature with 5% casein buffer. After washing, Aβ aggregate solu-
tions were added to the plate and incubated for 1 h at room temperature. The plate was washed
again and bound Aβ aggregates were detected by biotinylated 6E10/HRP-avidin mediated
immunoreaction (BioLegend, San Diego, CA USA) using TMB as detection reagent. Each
value was background corrected which were derived from ELISA of samples without capture
antibody and normalized to the control without peptide (0% no inhibition, 100% full inhibi-
tion). Mean value and standard error were calculated from three independent experiments.
EC50 was calculated by fitting the data to a logistic dose response function.
Aβ Aggregate disassembly ELISA
Freshly dissolved monomeric Aβ(1–42) (400 nM in 500 mM Tris-buffer pH 7.4) was incubated
in a humidity chamber for 22 h at 37°C in order to preform Aβ(1–42) aggregates. These pre-
formed aggregates were coincubated with D-peptide in different concentrations (0.01, 0.05, 0.1,
0.5, 1, 5, 10, 50, 100 μM for DB3 or with half of the molar concentrations in case of DB3DB3)
for additional 22 h at 37°C. The content of Aβ aggregates was measured and evaluated in the
same way as the aggregation inhibition ELISA.
Transmission electron microscopy (TEM)
10 μM of freshly dissolved monomeric Aβ(1–42) was incubated in 10 mM sodium phosphate
buffer pH 7.4 with or without DB peptide in equal molar ratios for 24 h at 37°C. Afterwards,
20 μl of the samples were absorbed on formval/carbon coated copper grids (S162, Plano, Wet-
zlar, Germany) for 3 min, washed three times with water and negative stained with 1% v/v ura-
nylacetate for 1 min. The images were acquired using a Libra 120 electron microscope (Zeiss,
Oberkochen, Germany) at 120 kV.
Statistical analysis
Statistical analysis was performed using the Origin 8.5 (OriginLab Cooperation, Northampton,
USA) software package.
Results
Screening for optimized D3 derivatives using peptide microarrays
We identified previously the Aβ oligomer eliminating D-enantiomeric peptide D3 via mirror
image phage display [10, 16]. A possible explanation of the efficiency of D3 is that it binds to
and stabilizes Aβmonomers within the various equilibria with Aβ oligomers and other Aβ
assemblies. In order to identify more efficient derivatives, a systematic optimization of D3
regarding its binding affinity to monomeric Aβ(1–42) was performed using a two-step proce-
dure. For the first step, every position of the original peptide D3 was replaced against each of
the 19 other proteinogenic amino acids residues in their D-enantiomeric form. These 20x12
different peptides were spotted on a Pepspot membrane (JPT, Berlin, Germany) and the bind-
ing of monomeric Aβ(1–42) was measured according to the procedure described in the mate-
rial and method part. To verify that the applied Aβ(1–42) was mainly monomeric even after
the 1 h incubation period, a density gradient ultracentrifugation run was done with an aliquot
of the applied Aβ(1–42) that was incubated 1 h, too. Even after 1 h incubation, only a very
small fraction of Aβ(1–42) was found in fractions 4 and higher (Fig 1) indicating that by far the
largest part of the Aβ is still monomeric and thus can be found in fractions 1 to 3 [14]. After
washing, the amount of bound Aβ was determined by the Aβ-specific antibody 6E10, which is
known to bind all Aβ species regardless of their assembly state, and a secondary detection
Optimization of the All-D Peptide D3 for AβOligomer Elimination
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antibody (Fig 2A). The amino acid substitutions that yielded the highest Aβ binding activity, as
measured by the dot staining density, were chosen for further combinations in the second
round (Fig 2B and 2C). In particular, the substitutions R3I, R5T, H9D, R10Q, R10E, N11Q and
N11D were found to bind more favorably to Aβmonomers. The residue H7 showed the highest
potential for further improvement, because most substitutions at this position yielded higher
affinity towards Aβmonomers. H7P, H7Q, H7R and H7S were selected as the most promising
substitutions for H7. Substitution of R12 was excluded from the analysis because a minimum
number of arginines has been recognized to be responsible for the superior pharmacokinetic
properties of D3 [20]. Interestingly, nine of the eleven substitutions were located in the C-ter-
minal half of D3 at positions 7, 9, 10 and 11.
For the second round of optimization, every possible combination of the eleven single resi-
due replacements R3I, R5T, H7P, H7Q, H7R, H7S, H9D, R10Q, H10E, N11Q and N11D, were
combined to yield 360 different peptides, which were spotted on a glass chip (Pepscan, Lely-
stad, Netherlands) (Fig 2C). To compare their binding activities to monomeric Aβ, the peptide
microarrays were incubated with freshly dissolved monomeric FITC-Aβ(1–42) and fluores-
cence intensities of the Aβ-peptide interactions were measured. Five peptides that showed tight
binding to Aβmonomers as deduced from high FITC fluorescence intensities were chosen for
further in vitro characterization (Fig 2D and Table 1). The fluorescence intensities of these D3
derivatives, termed DB1 to DB5, were up to six times higher when compared with the fluores-
cence intensity obtained with D3 (Fig 2D). As shown in Table 1, the sequences of DB1 to DB5
had two to four amino acid substitutions to the original D3 template.
The influence of DB3 and DB3DB3 on Aβ fibril formation
To investigate the influence of DB1 to DB5 on Aβ fibril formation, a Thioflavin T (ThT) assay
was performed. In an aqueous environment the benzothiazole dye has a low fluorescence. Upon
interaction with regularly formed amyloid fibrils the fluorescence signal is significantly enhanced
and excitation and emission maxima shift from 385 and 445 nm to 450 and 490 nm, respectively.
The emission at 490 nm is directly proportional to the quantity of amyloid fibrils. Fibril forma-
tion of Aβ can be followed in real time by measuring the ThT fluorescence [21–23].
Therefore, the inhibitory effects of the D-peptides DB1 to DB5 and D3 were investigated by
co-incubating these peptides with Aβ(1–42) and performing the ThT assay. Fluorescence emis-
sion data were compared after 5 h incubation, because after this period the Aβ(1–42) control
(without added peptide) reached its fluorescence maximum. As shown in Fig 3, D3 inhibited
Fig 1. Aggregation state of monomeric Aβ(1–42) after 1 h incubation. For optimization of D3 with peptide
microarrays, the peptide microarrays were incubated with 5 μM initially monomeric Aβ(1–42) for 1 h at room
temperature. The aggregation state of this Aβ preparation was analyzed by density gradient centrifugation
followed by 16% Tricine-SDS-PAGE. FITC-Aβ(1–42) was detected via FITC fluorescence and was only
detectable in the first four lanes, which represent mainly monomeric and oligomeric FITC-Aβ [14].
doi:10.1371/journal.pone.0153035.g001
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Aβ(1–42) fibril formation by 30%, whereas DB3 inhibited the Aβ(1–42) fibril formation by
80%, DB5 by 76%, DB1 by 63% and DB2 by 49% when compared to the control (Fig 3). Sur-
prisingly, DB4 had no effect on the fibril formation of Aβ.
The results of the ThT assay indicate that DB3 is the most promising peptide according to
the inhibitory effect of fibril formation. Therefore, we selected DB3 for further in vitro studies.
As a further potential optimization step of the DB peptides, we wanted to investigate the
impact of avidity. Although the DB peptides were selected for monomer binding, elimination
Fig 2. Selection of DB1 to DB5 based on two cycles of peptidemicroarray based screenings. A) Promising replacements in the sequence of D3 were
selected via PepSpots peptide array. Binding of monomeric Aβ(1–42) to spotted D3 derivatives was detected using the Aβ antibody 6E10 and a HRP-labeled
secondary antibody. Several of the dots with the highest staining density, representing the most promising single replacements, are marked in red. The
original D3 controls are indicated in blue. B) The HRP-intensity was evaluated by the staining density of the peptide dots and plotted against the amino acid
substitutions. Eleven promising substitutions that showed > 1.5 times increase in binding to monomeric Aβ(1–42) when compared with that of D3, were
chosen for a second generation peptide microarray. The red line represents the mean dot staining intensity of D3. C) Schematic overview of the first
generation microarray output. D) Binding of FITC-Aβ(1–42) to the peptides DB1 to DB5. The binding of FITC-Aβ(1–42) to the spotted peptides was analyzed
by measuring the FITC-fluorescence intensity. All intensities were background corrected. The signal intensities of the top five peptides were plotted. The red
line represents the mean fluorescence intensity of D3.
doi:10.1371/journal.pone.0153035.g002
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of toxic oligomer species might require contacting monomer units within these oligomers. In
order to make use of the multivalence of oligomers, multivalent DB3 could possibly have
increased efficiency in oligomer elimination. As the simplest multivalent DB3 peptide, we
designed a head-to-tail tandem peptide of DB3, named DB3DB3. In contrast to other divalent
DB3 molecules, e.g. head-to-head or tail-to-tail orientations, the head-to-tail tandem of DB3
contains only peptide bonds between the amino acid residues and is thus easily accessible by
standard peptide synthesis. As shown in Fig 3, 10 μMDB3DB3 inhibited the formation of
ThT-positive aggregates as efficiently as 20 μMDB3.
Binding affinities of DB3 and DB3DB3 to Aβ(1–42) monomers
For further characterization of DB3 and DB3DB3, the equilibrium dissociation constants (KD)
of the D-peptides were determined for their interaction with Aβ(1–42) monomers using bio-
layer interferometry (BLI) (Fig 4). For DB3, a KD value of 75 μMwas determined, whereas for
the designed dimer peptide DB3DB3 a KD value of 1 μMwas obtained. Therefore, the binding
affinity to Aβ(1–42) monomers was enhanced by 75-fold for the dimeric version of DB3.
Aβ aggregation inhibition by DB3 and DB3DB3
To confirm and further investigate the efficiency of DB3 and DB3DB3 activity on Aβ aggrega-
tion, an aggregation inhibition ELISA was performed. Initially monomeric Aβ(1–42) was incu-
bated with different concentrations of DB3 or DB3DB3 and the Aβ(1–42) aggregates were
specifically detected via ELISA. DB3 inhibits Aβ aggregate formation with an EC50 of 6 μM,
whereas DB3DB3 inhibits Aβ aggregate formation with an EC50 of 8 nM (Fig 5A). Thus,
DB3DB3 is 1000-fold more efficient in inhibiting Aβ aggregation when compared with that of
DB3. Furthermore, the aggregation inhibition ELISA showed that the fibrillization of Aβ(1–42)
was almost inhibited completely at a peptide concentration of 20 μMDB3 and 10 μMDB3DB3.
Aβ aggregates disassembly ability of DB3 and DB3DB3
The Aβ aggregate disassembly ELISA was used to analyze the effect of DB3 and DB3DB3 on
preformed Aβ aggregates (Fig 5B). Preformed Aβ(1–42) aggregates were co-incubated with dif-
ferent concentrations of DB3 or DB3DB3 for 24 h. The Aβ aggregates specific ELISA was used
to quantify Aβ aggregates. The raw data were normalized to Aβ aggregates without peptide.
The results of measured Aβ aggregates normalized to the Aβ control were plotted against the
peptide concentration. The EC50 was calculated by a logarithmic dose response function.
The EC50 value using D3 to dissemble the Aβ aggregates was 2.5 μM; however, the value for
DB3DB3 could not be determined because the Aβ aggregates were already disassembled at very
Table 1. Amino acid sequences of D3 and DB1 to DB5.
name sequence
D3 RPRTRLHTHRNR
DB1 RPITRLHTDRNR
DB2 RPITTLQTHQNR
DB3 RPITRLRTHQNR
DB4 RPRTRLRTHQNR
DB5 RPITRLQTHEQR
All amino acids of the peptides are D-enantiomeric and their C-termini are amidated. The amino acid
substitutions made to the D3 template are indicated in bold.
doi:10.1371/journal.pone.0153035.t001
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low peptide concentrations, i.e., addition of 10 nM DB3DB3 to 400 nM Aβ gave 80% disassem-
bly of the Aβ aggregates when compared to Aβ in the absence of peptide.
Elimination of Aβ oligomers
Aβ oligomers are the main toxic species and are discussed to be responsible for development
and progression of AD [7]. A promising therapeutic approach is the elimination of Aβ oligo-
mers. We have previously established an assay that determines quantitatively the Aβ oligomer
elimination efficiency of a given substance (QIAD assay) [14]. By applying this assay the Aβ(1–
42) oligomer elimination efficacy of DB3 and DB3DB3 (Fig 6) was determined. Incubation of
80 μMmonomeric Aβ(1–42) for 4.5 h led to the formation of a mixture of Aβmonomers
Fig 3. Thioflavin T fibril formation assay. 20 μMAβ(1–42) was mixed with 20 μMDB1 to DB5 or 10 μM
DB3DB3 and the ThT fluorescence was monitored. Aβ(1–42) without peptide addition was taken as the
control. The ThT fluorescence of all samples were compared after 5 h, where the control, Aβ(1–42) only,
reached its maximum in fluorescence emission. The Mann-Whitney-U-test was used for statistical analysis. *
p < 0.05; ** p < 0.01; *** p < 0.001.
doi:10.1371/journal.pone.0153035.g003
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(fractions 1–2), oligomers (fractions 4–6) and larger aggregates (other fractions) (Fig 6A).
Addition of DB3 at different concentrations resulted in the elimination of Aβ oligomers in a
concentration-dependent manner. Addition of 40 μMDB3 to Aβ oligomers yielded near com-
plete elimination of the oligomers. In comparison, addition of 20 μMDB3DB3 to 80 μMAβ
eliminated the oligomer species completely. Moreover, the content of Aβ oligomers was also
strongly reduced when applying 10 μMDB3DB3.
RP-HPLC was used to quantify the Aβ oligomer elimination efficiency (Fig 6B). 20 μMDB3
reduced the amount of Aβ oligomers by ~27% compared with that of the Aβ only control.
10 μMDB3DB3 reduced the content of Aβ oligomers by 82%, which is a significant improve-
ment over the DB3 result. The content of large co-precipitates increased and represented the
content of Aβ oligomers that were eliminated. The content of monomeric Aβ was not affected
by DB3 and DB3DB3. Thus, DB3 and DB3DB3 eliminated Aβ oligomers without affecting the
monomers and shifted the equilibrium from oligomeric Aβ to larger Aβ aggregates.
Reduction of Aβ toxicity
The MTT assay with rat PC12 cells was performed to analyze the influence of DB3 and
DB3DB3 to Aβ-induced cytotoxicity (Fig 7). Monomeric Aβ(1–42) was pre-incubated for 4.5 h
Fig 4. KD determination of DB3 and DB3DB3 to monomeric Aβ using biolayer interferometry (BLI).N-terminally biotinylated Aβ(1–42) monomers were
immobilized on streptavidin biosensors and the binding of DB3 and DB3DB3 was detected. Representative double referenced sensorgrams of a dilution
series of DB3 (A) and DB3DB3 (B) are shown, including the equilibrium dissociation constants (KD) as means ± SD of data recorded in triplicate. For steady
state analysis Langmuir´s 1:1 binding model was applied. Representative fits of DB3 (C) and DB3DB3 (D) are depicted with the corresponding corrected R2.
doi:10.1371/journal.pone.0153035.g004
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to yield Aβ oligomers. After additional co-incubation with DB3 or DB3DB3 for 40 min, the
mixture was added to PC12 cells and cell viability was analyzed after 24 h using the MTT assay.
In the absence of peptides a solution of 1 μMAβ reduced the PC12 cell viability to 44% (Fig
7). In contrast, neither DB3 (5 μM) nor DB3DB3 (5 μM) exhibited any effect on PC12 cell via-
bility, which indicates that both peptides are not toxic at the applied concentration. Addition
of DB3 to 1 μM pre-incubated Aβ over the concentration range of 0.2 to 5 μM did not signifi-
cantly increase cell viability. However, a significant concentration-dependent increase of cell
viability was observed in the presence of 0.1 to 2.5 μMDB3DB3 in a concentration dependent
manner up to 80% (Fig 7). Thus, DB3DB3 was able to inhibit Aβ-induced cytotoxicity.
Morphology of co-incubated Aβ
To analyze the morphology of Aβ co-complexes with DB3 and DB3DB3, initially monomeric
Aβ(1–42) was incubated with DB3 and DB3DB3 for 24 h and TEM analysis performed. For
Fig 5. Inhibition of Aβ fibril formation and Aβ aggregation disassemble by DB3 and DB3DB3. A) Monomeric Aβ(1–42) (400 nM) was mixed with
different concentrations of DB3 (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 μM) and the aggregation state of Aβ was analyzed using an Aβ aggregate specific
ELISA. For DB3DB3 half of the molar concentrations compared to DB3 were used. Aβwithout DB3 and DB3DB3 addition was taken as control. For DB3 an
EC50 of 6 μMwas calculated using a logistic fit model. DB3DB3 inhibited the formation of Aβ fibrils more efficiently with an EC50 of 7 nM. B) The disassembly
properties of DB3 and DB3DB3 were measured using an Aβ aggregation specific ELISA. Monomeric Aβ(1–42) (400 nM) was preincubated in order to form
fibrils and mixed with nine different concentrations of DB3 (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100 μM). For DB3DB3, the molar concentrations were half those
used for DB3. For DB3 an EC50 of 2.5 μMwas determined. DB3DB3 disassembled Aβ aggregates at the lowest concentration (10 nM). Thus, the EC50 could
not be determined, but is < 10 nM. All data were determined in triplicate. The Mann-Whitney-U-test was performed for statistical analysis. * p< 0.05; **
p < 0.01; *** p < 0.001
doi:10.1371/journal.pone.0153035.g005
Optimization of the All-D Peptide D3 for AβOligomer Elimination
PLOS ONE | DOI:10.1371/journal.pone.0153035 April 22, 2016 11 / 16
TEM analysis, the samples were absorbed onto formval/copper grids and negatively stained
using uranyl acetate.
Aβ formed large meshes of fibrils after 24 h incubation (Fig 8A). Co-incubation of Aβ with
DB3 in an equal molar ratio resulted in the formation of substantially fewer and shorter fibrils
(Fig 8B), which is in perfect accordance with the observation from the ThT assay that DB3 was
able to reduce fibril formation by 80%. Co-incubation of Aβ with DB3DB3 yielded huge amor-
phous co-precipitates, which did not contain any fibrillar structures (Fig 8C). Obviously, at
least under these artificially high concentrations, DB3DB3 did not yield mostly Aβmonomers,
but high-molecular-weight non-fibrillar co-precipitates with Aβ (Fig 8C), as also observed in
the QIAD assay (Fig 6).
Discussion
Currently, there is no causal therapy for Alzheimer’s disease (AD). In vitro and in vivo studies
showed that Aβ oligomers play an important role in the progression of AD [7]. Therefore,
elimination of these toxic Aβ oligomers is a promising strategy to retard AD. Using peptide
microarrays, we have optimized the amino acid sequence of the well-characterized D-enantio-
meric Aβ oligomer-eliminating peptide D3. The most promising D3 derivatives, DB1–DB5,
exhibit two to four different amino acids compared with D3. Besides DB4, the DB peptides
have a lower net charge than D3, due to the substitution of R3, R5 and R10, and the introduc-
tion of negatively charged amino acids. The substitution of R10Q within DB4 was charge com-
pensated through the substitution H7R. Additional substitutions that had no effect to the net
charge were H7Q and N11Q. Combination of single amino acid residue replacements within
D3 that each showed slightly enhanced binding capabilities to monomeric FITC-Aβ (Fig 2B)
ultimately yielded D3 derivatives that are characterized by significantly enhanced binding
capabilities to monomeric FITC-Aβ (Fig 2D). Increased binding capabilities to monomeric
Fig 6. Effect of DB3 and DB3DB3 on different Aβ aggregation species. A) Analysis of Aβ(1–42) aggregation species with density gradient centrifugation
and followed by analysis using silver-stained Tricine-SDS-PAGE to analyze the influence of DB3 and DB3DB3 on the distribution of Aβ assemblies. B)
Quantification of Aβ(1–42) by RP-HPLC. All data were recorded in triplicate.
doi:10.1371/journal.pone.0153035.g006
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FITC-Aβ were solely deduced from fluorescence intensities. Although we cannot prove that
this assumption holds true for each peptide spot, it allowed us to pre-select the five most prom-
ising D3 derivatives that subsequently were compared to each other.
The inhibition efficacy of Aβ aggregation by DB1 to DB5 was investigated. DB3 was found
to be the most promising D3 derivative that inhibited the Aβ aggregation by up to 80%. In con-
trast, D3 inhibited Aβ aggregation by only 30%. Considering the results of the ThT assay, DB3
was chosen for further in vitro characterization. BLI analysis revealed that DB3 interacts with
Aβmonomers with a binding affinity of 75 μM, and an ELISA showed that DB3 inhibits the
formation of Aβ aggregates with an EC50 of 6 μM.
The D-enantiomeric peptides D3 and DB1–DB5 were developed for elimination of Aβ oligo-
mers. This was tested by the QIAD assay [14]. The addition of DB3 to Aβ reduced Aβ oligo-
mers by 28%. Aβmonomers, which are assumed to have neuroprotective functions [24], were
Fig 7. Influence of DB3 and DB3DB3 on Aβ-introduced cytotoxicity. The cell viability assay was performed using PC12 cells in a MTT test. Therefore, Aβ
(1–42) was preincubated for 4.5 h and further coincubated with DB3 or DB3DB3 for 40 min. The cells were incubated for 24 h with the Aβ(1–42)-peptide
mixture or Aβ(1–42) alone as a control. The absorption of buffer treated cells was set to 100% cell viability. The cell viability of cells treated with Aβ and DB3
or DB3DB3 were compared with cells treated with Aβ only. The Mann-Whitney-U-test was used for statistical analysis. * p < 0.05; ** p < 0.01; *** p < 0.001.
doi:10.1371/journal.pone.0153035.g007
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not affected. The reduction of oligomeric Aβ resulted in an increase of large amorphous Aβ co-
precipitates. TEM images showed that these aggregates possess a higher density. Typical Aβ
fibrils, which are linear, unbranched and 5 to 10 nm wide [25], were not visible. Additionally,
DB3 was able to disassemble preformed Aβ aggregates.
Since Aβ oligomers are a multivalent target, the divalent tandem peptide DB3DB3 was
expected to be significantly more effective. DB3DB3 showed a 75-fold higher affinity for Aβ
monomers. This increase in affinity resulted in an increase in the inhibition of Aβ fibrilation
and an increased reduction in Aβ-induced cytotoxicity. Additionally, in the Aβ aggregation
inhibition ELISA, DB3DB3 yielded an EC50 that was 1000-fold lower when compared with that
of DB3. DB3DB3 was also able to efficiently eliminate Aβ oligomers as shown in the QIAD
assay. Interestingly, DB3 and DB3DB3 did not significantly affect the Aβmonomer content.
TEM images showed that these aggregates were not fibrillary structured.
In summary, our in vitro data show that the D3 derivative DB3 and its tandem version
DB3DB3 were highly efficient at reducing Aβ oligomer content in samples. In particular, the
tandem peptide DB3DB3 yielded a significant optimization step when compared with the orig-
inal peptide DB3. In vivo studies will show whether the new compounds’ in vitro properties
can be translated into enhanced therapeutic activity in AD animal models.
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Fig 8. TEM of Aβ-DB3 and -DB3DB3 co-complexes. 10 μM initial monomeric Aβ(1–42) without (A) and with 10 μMDB3 (B) or 5 μMDB3DB3 (C) were
coincubated for 24 h. Subsequently, the samples were absorbed onto formval/carbon coated copper grids and negative stained with 1% uranyl acetate. The
images were obtained using a transmission electron microscope (TEM). Scale bar: 0.25 μm.
doi:10.1371/journal.pone.0153035.g008
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